Clinical trials statistics are based on clinicaltrials.gov data found as a result of search queries that contained the names of the platforms: human adenoviral vector (Ad5, Ad26, and others), chimpanzee adenoviral vector (ChAd3, ChAd63, and others), and mRNA vaccine.
Scientific articles statistics are based on pubmed.ncbi.nlm.nih.gov data found as a result of search queries that contained the names of the platforms.
* Selected examples of articles on the safety of human adenovirus vectors (77 articles)
The use of adenovirus vector technology for vector vaccines has been gaining momentum since the 1980s, and is safe and effective, which has been proven in multiple studies.
The Gamaleya National Center of Epidemiology and Microbiology is the world’s leading research institution founded in 1891.
The center runs one of the unique “virus libraries” in the world and has its own vaccine production facility. Gamaleya Research Center has recently received an international patent for Ebola vaccine using adenovirus vector.
The vaccine has received a registration certificate from the Russian Ministry of Health and under emergency rules adopted during the COVID-19 pandemic can be used to vaccinate the population in Russia.
Russia is open to international cooperation in fighting the global threat of the COVID-19 pandemic as well as future pandemics. We are planning to cooperate with partners in other countries in making their vaccines in Russia as well as in producing our vaccine abroad. We therefore welcome all interested parties to join this effort and help us save people's lives.